Originally published as JCO Early Release 10.1200/JCO.2005.09.121 on November 15 2004
Journal of Clinical Oncology, Vol 23, No 3 (January 20), 2005: pp. 619-629
© 2005 American Society of Clinical Oncology.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Eric P. Winer,
Clifford Hudis,
Harold J. Burstein,
Antonio C. Wolff,
Kathleen I. Pritchard,
James N. Ingle,
Rowan T. Chlebowski,
Richard Gelber,
Stephan B. Edge,
Julie Gralow,
Melody A. Cobleigh,
Eleftherios P. Mamounas,
Lori J. Goldstein,
Timothy J. Whelan,
Trevor J. Powles,
John Bryant,
Cheryl Perkins,
Judy Perotti,
Susan Braun,
Amy S. Langer,
George P. Browman,
Mark R. Somerfield
From Cancer Policy and Clinical Affairs, American Society of Clinical Oncology, Alexandria, VA
Address reprint requests to Eric P. Winer, MD, Dana-Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115; e-mail: ewiner{at}partners.org
PURPOSE: To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors.
RECOMMENDATIONS: Based on results from multiple large randomized trials, adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Neither the optimal timing nor duration of aromatase inhibitor therapy is established. Aromatase inhibitors are appropriate as initial treatment for women with contraindications to tamoxifen. For all other postmenopausal women, treatment options include 5 years of aromatase inhibitors treatment or sequential therapy consisting of tamoxifen (for either 2 to 3 years or 5 years) followed by aromatase inhibitors for 2 to 3, or 5 years. Patients intolerant of aromatase inhibitors should receive tamoxifen. There are no data on the use of tamoxifen after an aromatase inhibitor in the adjuvant setting. Women with hormone receptor–negative tumors should not receive adjuvant endocrine therapy. The role of other biomarkers such as progesterone receptor and HER2 status in selecting optimal endocrine therapy remains controversial. Aromatase inhibitors are contraindicated in premenopausal women; there are limited data concerning their role in women with treatment-related amenorrhea. The side effect profiles of tamoxifen and aromatase inhibitors differ. The late consequences of aromatase inhibitor therapy, including osteoporosis, are not well characterized.
CONCLUSION: The Panel believes that optimal adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen. Women with breast cancer and their physicians must weigh the risks and benefits of all therapeutic options.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Gnant, P. Blaha, P. Dubsky, R. Exner, F. Fitzal, E. Sporn, P. Panhofer, A. Dal Borgo, S. Bigenzahn, G. Steger, et al.
Review: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
Therapeutic Advances in Medical Oncology,
November 1, 2009;
1(3):
123 - 136.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. T. Chlebowski
Aromatase Inhibitor-Associated Arthralgias
J. Clin. Oncol.,
October 20, 2009;
27(30):
4932 - 4934.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rabaglio, Z. Sun, K. N. Price, M. Castiglione-Gertsch, H. Hawle, B. Thurlimann, H. Mouridsen, M. Campone, J. F. Forbes, R. J. Paridaens, et al.
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Ann. Onc.,
September 1, 2009;
20(9):
1489 - 1498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The BIG 1-98 Collaborative Group
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
N. Engl. J. Med.,
August 20, 2009;
361(8):
766 - 776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kimmick, R. Anderson, F. Camacho, M. Bhosle, W. Hwang, and R. Balkrishnan
Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer
J. Clin. Oncol.,
July 20, 2009;
27(21):
3445 - 3451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hadji, M. Ziller, D. G. Kieback, W. Dornoff, H. W. Tessen, T. Menschik, J. Kuck, F. Melchert, and A. Hasenburg
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Ann. Onc.,
July 1, 2009;
20(7):
1203 - 1209.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Santen, H. Brodie, E. R. Simpson, P. K. Siiteri, and A. Brodie
History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target
Endocr. Rev.,
June 1, 2009;
30(4):
343 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Kataja, M. Castiglione, and On behalf of the ESMO Guidelines Working Group
Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv10 - iv14.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Falandry, P. A. Canney, G. Freyer, and L. Y. Dirix
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer
Ann. Onc.,
April 1, 2009;
20(4):
615 - 620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Seruga and I. F. Tannock
Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes
J. Clin. Oncol.,
February 20, 2009;
27(6):
840 - 842.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Postlberger, C. Menzel, R. Jakesz, M. Seifert, M. Hubalek, V. Bjelic-Radisic, et al.
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
N. Engl. J. Med.,
February 12, 2009;
360(7):
679 - 691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Saad, J. D. Adachi, J. P. Brown, L. A. Canning, K. A. Gelmon, R. G. Josse, and K. I. Pritchard
Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer
J. Clin. Oncol.,
November 20, 2008;
26(33):
5465 - 5476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Avis
Breast Cancer Survivors and Hot Flashes: The Search for Nonhormonal Treatments
J. Clin. Oncol.,
November 1, 2008;
26(31):
5008 - 5010.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Jiang, N. M. Patterson, Y. Ling, J. Xie, W. G. Helferich, and D. J. Shapiro
Low Concentrations of the Soy Phytoestrogen Genistein Induce Proteinase Inhibitor 9 and Block Killing of Breast Cancer Cells by Immune Cells
Endocrinology,
November 1, 2008;
149(11):
5366 - 5373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Ellis, H. G. Bone, R. Chlebowski, D. Paul, S. Spadafora, J. Smith, M. Fan, and S. Jun
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
J. Clin. Oncol.,
October 20, 2008;
26(30):
4875 - 4882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Lester, D. Dodwell, O. P. Purohit, S. A. Gutcher, S. P. Ellis, R. Thorpe, J. M. Horsman, J. E. Brown, R. A. Hannon, and R. E. Coleman
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
Clin. Cancer Res.,
October 1, 2008;
14(19):
6336 - 6342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Hayes, V. Stearns, J. Rae, and D. Flockhart
Response: Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis
J Natl Cancer Inst,
September 17, 2008;
100(18):
1333 - 1334.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. McElroy, M. M. Shafer, R. E. Gangnon, L. A. Crouch, and P. A. Newcomb
Urinary Lead Exposure and Breast Cancer Risk in a Population-Based Case-Control Study
Cancer Epidemiol. Biomarkers Prev.,
September 1, 2008;
17(9):
2311 - 2317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Hernandez, H. T. Sorensen, J. Jacobsen, L. Pedersen, and T. L. Lash
Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association
Cancer Epidemiol. Biomarkers Prev.,
September 1, 2008;
17(9):
2509 - 2511.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Gibson and C. L O'Bryant
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors
Journal of Oncology Pharmacy Practice,
September 1, 2008;
14(3):
139 - 145.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. M. Brewster, G. N. Hortobagyi, K. R. Broglio, S.-W. Kau, C. A. Santa-Maria, B. Arun, A. U. Buzdar, D. J. Booser, V. Valero, M. Bondy, et al.
Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy
J Natl Cancer Inst,
August 20, 2008;
100(16):
1179 - 1183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Hershman
Getting a Grip on Aromatase Inhibitor-Associated Arthralgias
J. Clin. Oncol.,
July 1, 2008;
26(19):
3120 - 3121.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Hayes, V. Stearns, J. Rae, D. Flockhart, and on behalf of the Consortium on Breast Cancer Pharm
A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?
J Natl Cancer Inst,
May 7, 2008;
100(9):
610 - 613.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. C. Tam and S. J. Hotte
Consistency of Phase III Clinical Trial Abstracts Presented at an Annual Meeting of the American Society of Clinical Oncology Compared With Their Subsequent Full-Text Publications
J. Clin. Oncol.,
May 1, 2008;
26(13):
2205 - 2211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Goss, J. N. Ingle, J. L. Pater, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, L. E. Shepherd, K. I. Pritchard, et al.
Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen
J. Clin. Oncol.,
April 20, 2008;
26(12):
1948 - 1955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Crivellari, Z. Sun, A. S. Coates, K. N. Price, B. Thurlimann, H. Mouridsen, L. Mauriac, J. F. Forbes, R. J. Paridaens, M. Castiglione-Gertsch, et al.
Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial
J. Clin. Oncol.,
April 20, 2008;
26(12):
1972 - 1979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chia, W. Gradishar, L. Mauriac, J. Bines, F. Amant, M. Federico, L. Fein, G. Romieu, A. Buzdar, J. F.R. Robertson, et al.
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT
J. Clin. Oncol.,
April 1, 2008;
26(10):
1664 - 1670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Hadji
Menopausal symptoms and adjuvant therapy-associated adverse events
Endocr. Relat. Cancer,
March 1, 2008;
15(1):
73 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. U. Lin and E. P. Winer
Advances in Adjuvant Endocrine Therapy for Postmenopausal Women
J. Clin. Oncol.,
February 10, 2008;
26(5):
798 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Kahn
Moving Research From Bench to Bedside to Community: There Is Still More to Do
J. Clin. Oncol.,
February 1, 2008;
26(4):
523 - 526.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Rugo
The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
Ann. Onc.,
January 1, 2008;
19(1):
16 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Mouridsen, A. Keshaviah, A. S. Coates, M. Rabaglio, M. Castiglione-Gertsch, Z. Sun, B. Thurlimann, L. Mauriac, J. F. Forbes, R. Paridaens, et al.
Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial
J. Clin. Oncol.,
December 20, 2007;
25(36):
5715 - 5722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Jakesz, R. Greil, M. Gnant, M. Schmid, W. Kwasny, E. Kubista, B. Mlineritsch, C. Tausch, M. Stierer, F. Hofbauer, et al.
Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
J Natl Cancer Inst,
December 19, 2007;
99(24):
1845 - 1853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Prowell and V. Stearns
Extended Adjuvant Therapy for Breast Cancer How Much Is Enough?
J Natl Cancer Inst,
December 19, 2007;
99(24):
1825 - 1827.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Jones, J. Cantrell, S. Vukelja, J. Pippen, J. O'Shaughnessy, J. L. Blum, R. Brooks, N. L. Hartung, A. G. Negron, D. A. Richards, et al.
Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy
J. Clin. Oncol.,
October 20, 2007;
25(30):
4765 - 4771.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Winer, J. R. Harris, B. L. Smith, H. A. D'Alessandro, and E. F. Brachtel
Case 32-2007 -- A 62-Year-Old Woman with a Second Breast Cancer
N. Engl. J. Med.,
October 18, 2007;
357(16):
1640 - 1648.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Burstein and E. P. Winer
Aromatase Inhibitors and Arthralgias: A New Frontier in Symptom Management for Breast Cancer Survivors
J. Clin. Oncol.,
September 1, 2007;
25(25):
3797 - 3799.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Pruthi, J. C. Boughey, K. R. Brandt, A. C. Degnim, G. K. Dy, M. P. Goetz, E. A. Perez, C. A. Reynolds, P. J. Schomberg, and J. N. Ingle
A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations
Mayo Clin. Proc.,
September 1, 2007;
82(9):
1131 - 1140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dellapasqua, M. Colleoni, M. Castiglione, and A. Goldhirsch
New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies
Oncologist,
August 1, 2007;
12(8):
952 - 959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Ann. Onc.,
July 1, 2007;
18(7):
1133 - 1144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. R. Robertson
Fulvestrant (Faslodex(R)) How to Make a Good Drug Better
Oncologist,
July 1, 2007;
12(7):
774 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Hayes
Follow-up of Patients with Early Breast Cancer
N. Engl. J. Med.,
June 14, 2007;
356(24):
2505 - 2513.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss
Breast Cancer in the Elderly
J. Clin. Oncol.,
May 10, 2007;
25(14):
1882 - 1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Brufsky, W. G. Harker, J. T. Beck, R. Carroll, E. Tan-Chiu, C. Seidler, J. Hohneker, L. Lacerna, S. Petrone, and E. A. Perez
Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer
J. Clin. Oncol.,
March 1, 2007;
25(7):
829 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nichols
The Fight Against Tamoxifen Resistance in Breast Cancer Therapy: A New Target in the Battle?
Mol. Interv.,
February 1, 2007;
7(1):
13 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Younis, D Rayson, R Dewar, and C Skedgel
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer
Ann. Onc.,
February 1, 2007;
18(2):
293 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Greenspan, R. K. Bhattacharya, S. M. Sereika, A. Brufsky, and V. G. Vogel
Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
J. Clin. Endocrinol. Metab.,
January 1, 2007;
92(1):
131 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kennecke, I. Olivotto, C Speers, B Norris, S. Chia, C Bryce, and K. Gelmon
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen
Ann. Onc.,
January 1, 2007;
18(1):
45 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Perey, R Paridaens, H Hawle, K Zaman, F Nole, H Wildiers, M Fiche, D Dietrich, P Clement, D Koberle, et al.
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Ann. Onc.,
January 1, 2007;
18(1):
64 - 69.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Goldhirsch, A. Coates, R. Gelber, J. Glick, B Thurlimann, H-J Senn, and On behalf of the St Gallen Expert Panel Members
First--select the target: better choice of adjuvant treatments for breast cancer patients
Ann. Onc.,
December 1, 2006;
17(12):
1772 - 1776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Chien and P. E. Goss
Aromatase Inhibitors and Bone Health in Women With Breast Cancer
J. Clin. Oncol.,
November 20, 2006;
24(33):
5305 - 5312.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez
Appraising Adjuvant Aromatase Inhibitor Therapy
Oncologist,
November 1, 2006;
11(10):
1058 - 1069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Van Poznak and D. F. Hayes
Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
J Natl Cancer Inst,
September 20, 2006;
98(18):
1261 - 1263.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. U Buzdar and J. F. Robertson
Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer
Ann. Pharmacother.,
September 1, 2006;
40(9):
1572 - 1582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Ryan and P. E. Goss
Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer
Oncologist,
July 1, 2006;
11(7):
718 - 731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. B. Elkin, A. Hurria, N. Mitra, D. Schrag, and K. S. Panageas
Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptor-Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort
J. Clin. Oncol.,
June 20, 2006;
24(18):
2757 - 2764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. E. Smith, M. Dowsett, Y.-S. Yap, G. Walsh, P. E. Lonning, R. J. Santen, and D. Hayes
Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines
J. Clin. Oncol.,
June 1, 2006;
24(16):
2444 - 2447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Altundag and N. K. Ibrahim
Aromatase inhibitors in breast cancer: an overview.
Oncologist,
June 1, 2006;
11(6):
553 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gill and D. Sargent
End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
Oncologist,
June 1, 2006;
11(6):
624 - 629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. U. Buzdar
St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy
Ann. Onc.,
May 1, 2006;
17(5):
878 - 879.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dowsett, J. Houghton, C. Iden, J. Salter, J. Farndon, R. A'Hern, R. Sainsbury, and M. Baum
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
Ann. Onc.,
May 1, 2006;
17(5):
818 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sonmezer and K. Oktay
Fertility preservation in young women undergoing breast cancer therapy.
Oncologist,
May 1, 2006;
11(5):
422 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. U. Buzdar, M. Baum, J. Cuzick, J. K. Erban, R. T. Chlebowski, A. S. Coates, H. Mouridsen, L. Mauriac, and the BIG 1-98 Collaborative Group
Letrozole or tamoxifen in early breast cancer.
N. Engl. J. Med.,
April 6, 2006;
354(14):
1528 - 1530.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Come
A 62-Year-Old Woman With a New Diagnosis of Breast Cancer
JAMA,
March 22, 2006;
295(12):
1434 - 1442.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Gerber, A. Krause, T. Reimer, I. Mylonas, J. Makovitzky, G. Kundt, and W. Janni
Anastrozole versus Tamoxifen Treatment in Postmenopausal Women with Endocrine-Responsive Breast Cancer and Tamoxifen-Induced Endometrial Pathology
Clin. Cancer Res.,
February 15, 2006;
12(4):
1245 - 1250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Ingle
Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer
Clin. Cancer Res.,
February 1, 2006;
12(3):
1031s - 1036s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. U. Buzdar and J. Cuzick
Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data
Clin. Cancer Res.,
February 1, 2006;
12(3):
1037s - 1048s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Smith and S. Chua
Medical treatment of early breast cancer. I: adjuvant treatment
BMJ,
January 7, 2006;
332(7532):
34 - 37.
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Breast International Group (BIG) 1-98 Collabor
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
N. Engl. J. Med.,
December 29, 2005;
353(26):
2747 - 2757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Demonty
Treatment Guidelines for Adjuvant Breast Cancer Are Moving Toward Double Standards: One for the Rich and One for the Poor
J. Clin. Oncol.,
December 20, 2005;
23(36):
9436 - 9437.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Hutson, R. R. Love, T. C. Havighurst, E. Rogers, and J. F. Cleary
Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer
Clin. Cancer Res.,
December 15, 2005;
11(24):
8722 - 8727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Crandall and J. P. Pregler
Update in Women's Health
Ann Intern Med,
December 6, 2005;
143(11):
823 - 829.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Kievit, M. J. Bolster, G. J. van der Wilt, P. Bult, F. B. J. M. Thunnissen, J. Meijer, L. J. A. Strobbe, J. H. G. Klinkenbijl, T. Wobbes, E. M. M. Adang, et al.
Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer
Ann. Onc.,
December 1, 2005;
16(12):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Punglia and H. J. Burstein
In Reply:
J. Clin. Oncol.,
November 20, 2005;
23(33):
8546 - 8547.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Davidson, M. Morrow, D. B. Kopans, and F. C. Koerner
Case 35-2005 -- A 56-Year-Old Woman with Breast Cancer and Isolated Tumor Cells in a Sentinel Lymph Node
N. Engl. J. Med.,
November 17, 2005;
353(20):
2177 - 2185.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cianfrocca and W. J. Gradishar
Controversies in the Therapy of Early Stage Breast Cancer
Oncologist,
November 1, 2005;
10(10):
766 - 779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Sieuwerts, M. E. Meijer-van Gelder, M. Timmermans, A. M.A.C. Trapman, R. R. Garcia, M. Arnold, A. J.W. Goedheer, H. Portengen, J. G.M. Klijn, and J. A. Foekens
How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study
Clin. Cancer Res.,
October 15, 2005;
11(20):
7311 - 7321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
Ann. Onc.,
October 1, 2005;
16(10):
1569 - 1583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Benson
The Use of Aromatase Inhibitors in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
J. Clin. Oncol.,
September 20, 2005;
23(27):
6807 - 6809.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Goss, J. N. Ingle, S. Martino, N. J. Robert, H. B. Muss, M. J. Piccart, M. Castiglione, D. Tu, L. E. Shepherd, K. I. Pritchard, et al.
Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
J Natl Cancer Inst,
September 7, 2005;
97(17):
1262 - 1271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. E. Krop and E. P. Winer
Ovarian Suppression for Breast Cancer: An Effective Treatment in Search of a Home
J. Clin. Oncol.,
September 1, 2005;
23(25):
5869 - 5872.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Ryan, D. B. Kopans, and D. C. Sgroi
Case 24-2005 - A 58-Year-Old Woman with Early-Stage Estrogen-Receptor-Positive Breast Cancer
N. Engl. J. Med.,
August 11, 2005;
353(6):
617 - 622.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Shapiro
Aromatase Inhibitors and Bone Loss: Risks in Perspective
J. Clin. Oncol.,
August 1, 2005;
23(22):
4847 - 4849.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M Staka, R. I Nicholson, and J. M W Gee
Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model
Endocr. Relat. Cancer,
July 1, 2005;
12(Supplement_1):
S85 - S97.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tralongo, A. Di Mari, and F. Ferrau'
Cognitive Impairment, Aromatase Inhibitors, and Age
J. Clin. Oncol.,
June 20, 2005;
23(18):
4243 - 4243.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Brueggemeier, J. C. Hackett, and E. S. Diaz-Cruz
Aromatase Inhibitors in the Treatment of Breast Cancer
Endocr. Rev.,
May 1, 2005;
26(3):
331 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kudachadkar and R. M. O'Regan
Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer
CA Cancer J Clin,
May 1, 2005;
55(3):
145 - 163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tondini and R. Labianca
Tailoring a tailored treatment: the importance of fine-tuning on the patient
Ann. Onc.,
May 1, 2005;
16(5):
683 - 685.
[Full Text]
[PDF]
|
|
|
|
|
|
|
When Should Aromatase Inhibitors Be Used as Adjuvant Therapy for Breast Cancer?
Journal Watch Women's Health,
April 6, 2005;
2005(406):
1 - 1.
[Full Text]
|
|
|
|
|
|
|
K. Strasser-Weippl and P. E. Goss
Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
J. Clin. Oncol.,
March 10, 2005;
23(8):
1751 - 1759.
[Full Text]
[PDF]
|
|
|
|
